http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3404026-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73f5e16a663035df37ee4d9409e2514e |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 |
filingDate | 2016-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24b5c1218341119778f66723c9a230ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e6be8c645d9907d6f2dea45b9bff3e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87aa833fcaf20ef426f237b22c5dd5fa |
publicationDate | 2018-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-3404026-A1 |
titleOfInvention | Pyrimido-isoquinolin-quinone derivative compounds, and pharmaceutically acceptable salts, isomers and tautomers thereof; pharmaceutical composition; preparation method; and use thereof in the treatment of diseases caused by bacteria and multidrug-resistant bacteria |
abstract | The present invention provides pyrimidine-isoquinolin-quinone derivatives of formula I, their salts, isomers, pharmaceutically acceptable tautomers; pharmaceutical composition; preparation procedure; and their use in the treatment of bacterial and resistant bacterial diseases, such as methicillin-resistant Staphylococcus aureus (MRSA), intermediate vancomycin-resistant Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococcus spp. (VRE), Enterococcus faecalis, Emerging Staphylococcus aureus with resistance to linezolid and/or bacterial strains not susceptible to daptomycin.n nWhere the radicals R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the work specifications of the present invention. |
priorityDate | 2015-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 351.